Physician

Carl Barsigian, MD

According to 2025 Medicare claims, Carl Barsigian, MD (NPI: 1871582569) practices hematology/oncology in the Scranton--Wilkes-Barre, PA market, with the plurality of this provider's patient population coming from Lackawanna, PA. This provider's primary affiliated billing organization is HEMATOLOGY AND ONCOLOGY ASSOCIATES OF NORTHEASTERN PA, PC (NPI: 1164538724; TIN: 232137083) and primary practice location at 18512-3169. Barsigian is affiliated with the Keystone ACO (ACO ID: A1552), participating under the MSSP model.

Barsigian's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 841 traditional Medicare patients, billed 153,810 HCPCS/CPT codes, and received $2,946,279 in Medicare payments. The top billing code was 82728 (Ferritin (blood protein) level). Part D data shows 1,230 prescription claims across 185 beneficiaries totaling $4,700,513 in drug costs, led by Brukinsa (Zanubrutinib). DME data shows 99 claims. Open Payments data shows 27 records totaling $3,388. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $1,798,293 to $2,946,279. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,037,244 to $4,700,513. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $3,128 to $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	747	190,025	$1,798,293
2016	727	213,703	$1,889,238
2017	757	175,792	$1,984,484
2018	736	184,646	$2,267,524
2019	842	250,281	$2,328,254
2020	879	232,150	$2,609,260
2021	897	313,500	$4,027,301
2022	922	210,462	$2,589,890
2023	967	175,225	$2,697,228
2024	841	153,810	$2,946,279

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	150	780	$1,037,244
2016	145	809	$1,894,336
2017	164	957	$2,267,992
2018	182	1,114	$3,185,584
2019	165	933	$2,633,507
2020	147	776	$2,956,822
2021	193	1,100	$4,734,826
2022	160	975	$5,103,140
2023	166	999	$3,486,344
2024	185	1,230	$4,700,513

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	49	$18,990
2016	N/R	22	$846
2017	N/R	35	$1,029
2018	N/R	N/R	N/R
2019	N/R	37	$3,991
2020	N/R	35	$1,161
2021	14	148	$7,003
2022	N/R	59	$1,797
2023	N/R	34	$1,002
2024	11	99	$2,660

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
82728	Ferritin (blood protein) level	353	726	$13
80053	Blood test, comprehensive group of blood chemicals	660	1,670	$10
83550	Iron binding capacity	352	723	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	701	2,100	$8
83540	Iron level	351	722	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Brukinsa	Zanubrutinib	64	1,920	$921,013
Calquence	Acalabrutinib Maleate	33	990	$503,033
Lenalidomide	Lenalidomide	43	1,078	$468,830
Xtandi	Enzalutamide	31	930	$453,955
Imbruvica	Ibrutinib	31	880	$424,663

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	22	$1,018
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	11	40	$734
J8530	Cyclophosphamide; oral, 25 mg	N	N/R	22	$708
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	15	$201

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	25	$1,098	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	2	$2,290	E.R. Squibb & Sons, L.L.C.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Carl Barsigian, MD?

Tedicare shows public-source Medicare data for Carl Barsigian, MD (NPI 1871582569), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Carl Barsigian, MD have ACO affiliation data?

Carl Barsigian, MD is shown with ACO affiliation data for Keystone ACO (MSSP, ACO ID A1552).

What billing organization is linked to Carl Barsigian, MD?

Carl Barsigian, MD is linked to HEMATOLOGY AND ONCOLOGY ASSOCIATES OF NORTHEASTERN PA, PC (billing NPI 1164538724) in the available physician profile data.

Does Carl Barsigian, MD have Open Payments data?

Carl Barsigian, MD has 27 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.